Drug Trial Radar · NCT00683800
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
Last checked: Nov 19, 2026Latest source record: Aug 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,186
Actual
Start
Jun 2008
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
Conditions
- Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SRDrug
Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
PlaceboDrug
Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4Time frame: Baseline and Week 4
- Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12Time frame: Baseline and Week 12
- Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4Time frame: Baseline and Week 4
- Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12Time frame: Baseline and Week 12
- Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) EventsTime frame: Baseline up to Month 12
Locations
121 sites in 2 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Glendale, Arizona
Pfizer Investigational Site
Peoria, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Jonesboro, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Vista, California
Pfizer Investigational Site
Walnut Creek, California
Pfizer Investigational Site
Colorado Springs, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Englewood, Colorado
Pfizer Investigational Site
Longmont, Colorado
Pfizer Investigational Site
New London, Connecticut
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Brooksville, Florida
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Daytona Beach, Florida
Pfizer Investigational Site
Fort Myers, Florida
Pfizer Investigational Site
Gainesville, Florida
Pfizer Investigational Site
Lake Worth, Florida
Pfizer Investigational Site
New Port Richey, Florida
Pfizer Investigational Site
Palm Harbor, Florida
Pfizer Investigational Site
Pembroke Pines, Florida
Pfizer Investigational Site
South Miami, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Decatur, Georgia
Pfizer Investigational Site
Decatur, Georgia
Pfizer Investigational Site
Savannah, Georgia
Pfizer Investigational Site
Boise, Idaho
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.